

Table 3: Prevalence of Testosterone Deficiency

| Author/Study | Number of Patients | Description of Population | Definition of Testosterone Deficiency | Method of Testosterone Deficiency Measurement | Prevalence of Testosterone Deficiency |
|---|---------------------------|--|---|---|--|
| Harman et al. 2000 ⁵ <i>Baltimore Longitudinal Aging Study (BLAS)</i> | 890 | Generally healthy, middle class, 87% white Age range: 20-91 years (mean 63.8) Mean BMI: 25.6 | TT <325 ng/dL or a FTI <0.153 Only one TT or FTI value needed to be in the deficient range to be considered testosterone deficient | Early morning samples from each subject's most recent and previous 3 visits as well as those from 10, 15, 20, 25, and 30 years prior were analyzed (3,565 samples total with a mean of 4 samples per patient). TT: RIA SHBG: RIA FT: FTI | 50-59 years: 12% 60-69 years: 19% 70-79 years: 28% >80 years: 49% |
| Araujo et al. 2004 ⁶ <i>Massachusetts Male Aging Study (MMAS)</i> | T1: 1,709 T2: 1,156 | Patients were evenly divided among 40-49 years, 50-59 years, and 60-70 years; 95% white | TT<200 ng/dL combined with three or more symptoms (reduced libido, ED, depression, lethargy, inability to concentrate, sleep disturbance, irritability, and depressed mood), or a total testosterone level between 200- 400 ng/dL with three or more symptoms and a free testosterone level < 8.9 ng/dL | Patients were evaluated at 2 time points (T1: 1987-1989; T2: 1995-1997) separated by a mean of 8.8 years, all testing was done on single samples taken in the morning. TT: RIA SHBG: RIA FT: Sodergard equation assessment of patient symptoms | T1 40-49 years: 4.1% 50-59 years: 4.5% 60-70 years: 9.4% T2 40-49 years: 7.1% 50-59 years: 11.5% 60-70 years: 22.8% |

| | | | | | |
|---|--------------|---|--|--|---|
| <p>Mulligan et al. 2006⁷</p> <p><i>Hypogonadism in Males (HIM)</i></p> | <p>2,098</p> | <p>All men ≥ 45 years (mean 60.5) undergoing routine evaluation by their primary care physicians, 82% white</p> <p>Mean BMI: 29.7</p> | <p>TT <300 ng/dL, or men who were previously diagnosed with testosterone deficiency and who were currently using testosterone therapy</p> | <p>All draws were performed between 8a.m. and noon.</p> <p>TT: RIA SHBG: RIA FT: equilibrium dialysis Bioavailable T: Ammonium sulfate precipitation</p> | <p>38.7% of study population</p> <p>Mean testosterone level 245 ng/dL</p> <p>17% increase in testosterone deficiency per decade of life</p> |
| <p>Wu et al. 2010⁸</p> <p><i>European Male Aging Study (EMAS)</i></p> | <p>3,219</p> | <p>Age range: 40-79 years (mean 57.9)</p> | <p>TT <317 ng/dL along with the three sexual symptoms (sexual function [e.g., decreased frequency of morning erections, decreased frequency of sexual thoughts, ED, physical symptoms [e.g., inability to perform vigorous activity, inability to walk more than 1 km, inability to bend, kneel or stoop], and psychological symptoms [e.g., loss of energy, sadness, fatigue])</p> | <p>Men evaluated by primary care physicians had a single lab draw prior to 10a.m. and were administered a series of questionnaires.</p> <p>TT: GCMS SHBG: Immunoassay FT: Vermeulen equation</p> | <p>2.1% of study population</p> |
| <p>BMI: body mass index, ED: erectile dysfunction, FT: free testosterone, FTI: free testosterone index, GCMS: gas chromatography mass spectrometry, RIA: radioimmunoassay, SHBG: Sex hormone binding globulin, TT: total testosterone</p> | | | | | |